Skip to main content
HR 1352 118th Congress House Health Congressional oversight Government studies and investigations Health care costs and insurance Medicare Prescription drugs

Increasing Access to Biosimilars Act of 2023

Introduced: March 3, 2023 Introduced by: Hudson, Richard Republican · North Carolina See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 9 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 17, 2024
Referred to the Subcommittee on Health.
Dec 6, 2023
Ordered to be Reported (Amended) by the Yeas and Nays: 44 - 0.
Dec 6, 2023
Committee Consideration and Mark-up Session Held
Dec 5, 2023
Committee Consideration and Mark-up Session Held
Nov 15, 2023
Forwarded by Subcommittee to Full Committee by Voice Vote.
Nov 15, 2023
Subcommittee Consideration and Mark-up Session Held
Mar 10, 2023
Referred to the Subcommittee on Health.
Mar 3, 2023
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Mar 3, 2023
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Increasing Access to Biosimilars Act of 2023

This bill requires the Centers for Medicare & Medicaid Services to establish a demonstration project to evaluate the benefits of providing additional payments to providers of biosimilars under Medicare. Specifically, under the demonstration project, participating providers receive an additional payment based on the difference between the costs to the provider of furnishing the biosimilar and the cost if the provider had furnished the underlying reference biological product instead.

What's happening now December 17, 2024

Referred to the Subcommittee on Health.

 Related & companion bills 1
  • S 3934 Related bill Increasing Access to Biosimilars Act of 2023
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 1352: Increasing Access to Biosimilars Act of 2023. 118th Congress. Open America. https://openamerica.io/bill/118-HR-1352/
MLA
"H.R. 1352: Increasing Access to Biosimilars Act of 2023." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-HR-1352/.
Bluebook (legal)
H.R. 1352, 118th Cong. (2026), https://openamerica.io/bill/118-HR-1352/.
Markdown link
[H.R. 1352: Increasing Access to Biosimilars Act of 2023](https://openamerica.io/bill/118-HR-1352/)
Report a problem